Partial Remission Definition: Validation based on the insulin dose-adjusted HbA1c (IDAA1C) in 129 Danish Children with New-Onset Type 1 Diabetes
2014; Wiley; Volume: 15; Issue: 7 Linguagem: Inglês
10.1111/pedi.12208
ISSN1399-5448
AutoresMarie Louise C Max Andersen, Philip Hougaard, Sven Pörksen, Lotte B. Nielsen, Siri Fredheim, Jannet Svensson, Jane Thomsen, Jennifer Vikre-Jørgensen, Thomas Hertel, Jacob S. Petersen, Lars Hansen, Henrik B. Mortensen,
Tópico(s)Pancreatic function and diabetes
ResumoPediatric DiabetesVolume 15, Issue 7 p. 469-476 Original Article Partial Remission Definition: Validation based on the insulin dose-adjusted HbA1c (IDAA1C) in 129 Danish Children with New-Onset Type 1 Diabetes† Marie Louise C Max Andersen, Marie Louise C Max Andersen Department of Pediatrics, Herlev Hospital, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, DenmarkSearch for more papers by this authorPhilip Hougaard, Philip Hougaard Department of Statistics, University of Southern Denmark, Odense, DenmarkSearch for more papers by this authorSven Pörksen, Sven Pörksen Department of Pediatrics, Herlev Hospital, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, DenmarkSearch for more papers by this authorLotte B Nielsen, Lotte B Nielsen Department of Pediatrics, Herlev Hospital, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, DenmarkSearch for more papers by this authorSiri Fredheim, Siri Fredheim Department of Pediatrics, Herlev Hospital, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, DenmarkSearch for more papers by this authorJannet Svensson, Jannet Svensson Department of Pediatrics, Herlev Hospital, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, DenmarkSearch for more papers by this authorJane Thomsen, Jane Thomsen Department of Pediatrics, Kolding Hospital, Kolding, DenmarkSearch for more papers by this authorJennifer Vikre-Jørgensen, Jennifer Vikre-Jørgensen Department of Pediatrics, Skejby University Hospital, Aarhus, DenmarkSearch for more papers by this authorThomas Hertel, Thomas Hertel H.C. Andersen Children's Hospital, Odense University Hospital, Odense, DenmarkSearch for more papers by this authorJacob S Petersen, Jacob S Petersen Diabetes Pharmacology and Bioanalysis, Novo Nordisk A/S, Måløv, DenmarkSearch for more papers by this authorLars Hansen, Lars Hansen Department of Pediatrics, Herlev Hospital, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, DenmarkSearch for more papers by this authorHenrik B Mortensen, Corresponding Author Henrik B Mortensen Department of Pediatrics, Herlev Hospital, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark Corresponding author: Henrik B Mortensen, Department of Pediatrics, Herlev Hospital, University of Copenhagen, 2730 Herlev, Denmark. Tel: +45 38685016; Fax: +45 38685012 e-mail: [email protected]Search for more papers by this author Marie Louise C Max Andersen, Marie Louise C Max Andersen Department of Pediatrics, Herlev Hospital, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, DenmarkSearch for more papers by this authorPhilip Hougaard, Philip Hougaard Department of Statistics, University of Southern Denmark, Odense, DenmarkSearch for more papers by this authorSven Pörksen, Sven Pörksen Department of Pediatrics, Herlev Hospital, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, DenmarkSearch for more papers by this authorLotte B Nielsen, Lotte B Nielsen Department of Pediatrics, Herlev Hospital, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, DenmarkSearch for more papers by this authorSiri Fredheim, Siri Fredheim Department of Pediatrics, Herlev Hospital, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, DenmarkSearch for more papers by this authorJannet Svensson, Jannet Svensson Department of Pediatrics, Herlev Hospital, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, DenmarkSearch for more papers by this authorJane Thomsen, Jane Thomsen Department of Pediatrics, Kolding Hospital, Kolding, DenmarkSearch for more papers by this authorJennifer Vikre-Jørgensen, Jennifer Vikre-Jørgensen Department of Pediatrics, Skejby University Hospital, Aarhus, DenmarkSearch for more papers by this authorThomas Hertel, Thomas Hertel H.C. Andersen Children's Hospital, Odense University Hospital, Odense, DenmarkSearch for more papers by this authorJacob S Petersen, Jacob S Petersen Diabetes Pharmacology and Bioanalysis, Novo Nordisk A/S, Måløv, DenmarkSearch for more papers by this authorLars Hansen, Lars Hansen Department of Pediatrics, Herlev Hospital, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, DenmarkSearch for more papers by this authorHenrik B Mortensen, Corresponding Author Henrik B Mortensen Department of Pediatrics, Herlev Hospital, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark Corresponding author: Henrik B Mortensen, Department of Pediatrics, Herlev Hospital, University of Copenhagen, 2730 Herlev, Denmark. Tel: +45 38685016; Fax: +45 38685012 e-mail: [email protected]Search for more papers by this author First published: 06 October 2014 https://doi.org/10.1111/pedi.12208Citations: 46 †This study was presented as poster at the 49th Annual Meeting of the European Association for the Study of Diabetes (EASD), Barcelona, Spain, 24–27 September 2013. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Abstract Objective To validate the partial remission (PR) definition based on insulin dose-adjusted HbA1c (IDAA1c). Subjects and methods The IDAA1c was developed using data in 251 children from the European Hvidoere cohort. For validation, 129 children from a Danish cohort were followed from the onset of type 1 diabetes (T1D). Receiver operating characteristic curve (ROC) analysis was used to evaluate the predictive value of IDAA1c and age on partial C-peptide remission (stimulated C-peptide, SCP > 300 pmol/L). Results PR (IDAA1c ≤ 9) in the Danish and Hvidoere cohorts occurred in 62 vs. 61% (3 months, p = 0.80), 47 vs. 44% (6 months, p = 0.57), 26 vs. 32% (9 months, p = 0.32) and 19 vs. 18% (12 months, p = 0.69). The effect of age on SCP was significantly higher in the Danish cohort compared with the Hvidoere cohort (p < 0.0001), likely due to higher attained Boost SCP, so the sensitivity and specificity of those in PR by IDAA1c ≤ 9, SCP > 300 pmol/L was 0.85 and 0.62 at 6 months and 0.62 vs. 0.38 at 12 months, respectively. IDAA1c with age significantly improved the ROC analyses and the AUC reached 0.89 ± 0.04 (age) vs. 0.94 ± 0.02 (age + IDAA1c) at 6 months (p < 0.0004) and 0.76 ± 0.04 (age) vs. 0.90 ± 0.03 (age + IDAA1c) at 12 months (p < 0.0001). Conclusions The diagnostic and prognostic power of the IDAA1c measure is kept but due to the higher Boost stimulation in the Danish cohort, the specificity of the formula is lower with the chosen limits for SCP (300 pmol/L) and IDAA1c ≤9, respectively. References 1Akirav E, Kushner JA, Herold KC. Beta-cell mass and type 1 diabetes: going, going, gone? Diabetes 2008: 57: 2883– 2888. 2Pescovitz MD, Greenbaum CJ, Bundy B et al. The T: B-lymphocyte depletion with rituximab and beta-cell function: two-year results. Diabetes Care 2014: 37: 453– 459. 3Orban T, Bundy B, Becker DJ et al. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatment. Diabetes Care 2014: 37: 1069– 1075. 4 The Diabetes Control and Complications Trial Research Group. The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes 1996: 45: 1289– 1298. 5 The Diabetes Control and Complications Trial Research Group. Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes 1997: 46: 271– 286. 6Komulainen J, Lounamaa R, Knip M, Kaprio EA, Akerblom HK. Ketoacidosis at the diagnosis of type 1 (insulin dependent) diabetes mellitus is related to poor residual beta cell functionChildhood Diabetes in Finland Study Group. Arch Dis Child 1996: 75: 410– 415. 7Ortqvist E, Björk E, Wallensteen M, Ludvigsson J et al. Temporary preservation of beta-cell function by diazoxide treatment in childhood type 1 diabetes. Diabetes Care 2004: 27: 2191– 2197. 8Schölin A, Nyström L, Arnqvist H et al. Proinsulin/C-peptide ratio, glucagon and remission in new-onset type 1 diabetes mellitus in young adults. Diabet Med 2011: 28: 156– 161. 9Buyukgebiz A, Cemeroglu AP, Bober E, Mohn A, Chiarelli F. Factors influencing remission phase in children with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 2001: 14: 1585– 1596. 10Mortensen HB, Hougaard P, Swift P et al. New definition for the partial remission period in children and adolescents with type 1 diabetes. Diabetes Care 2009: 32: 1384– 1390. 11Mortensen HB, Swift PGF, Holl RW et al. Multinational study in children and adolescents with newly diagnosed type 1 diabetes: association of age, ketoacidosis, HLA status, and autoantibodies on residual beta-cell function and glycemic control 12 months after diagnosis. Pediatr Diabetes 2010: 11: 218– 226. 12Andersen ML, Vaziri-Sani F, Delli A et al. Association between autoantibodies to the Arginine variant of the Zinc transporter 8 (ZnT8) and stimulated C-peptide levels in Danish children and adolescents with newly diagnosed type 1 diabetes. Pediatr Diabetes 2012: 13: 454– 462. 13Andersen MLM, Rasmussen MA, Pörksen S et al. Complex multi-block analysis identifies new immunologic and genetic disease progression patterns associated with the residual beta-cell function 1 year after diagnosis of type 1 diabetes. PLoS One 2013: 8: 1– 8. 14 The Diabetes Control and Complications Trial Research Group. Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the Diabetes Control and Complications Trial. Ann Intern Med 1998: 128: 517– 523. 15Seshan VE, Gönen M, Begg CB. Comparing ROC curves derived from regression models. Stat Med 2013: 32: 1483– 1493. 16Caprio S, Plewe G, Diamond MP, Simonson DC et al. Increased insulin secretion in puberty: a compensatory response to reductions in insulin sensitivity. J Pediatr 1989: 114: 963– 967. 17Smith CP, Archibald HR, Thomas JM et al. Basal and stimulated insulin levels rise with advancing puberty. Dev Biol 1987: 28: 7– 14. 18Jeffery AN, Metcalf BS, Hosking J, Streeter AJ, Voss LD, Wilkin TJ. Age before stage: insulin resistance rises before the onset of puberty: a 9-year longitudinal study (EarlyBird 26). Diabetes Care 2012: 35: 536– 541. 19Neylon OM, White M, ÓConnell MA, Cameron FJ. Insulin-dose-adjusted HbA1c-defined partial remission phase in a paediatric population-when is the honeymoon over? Diabet Med 2013: 30: 627– 628. 20Bowden SA, Duck MM, Hoffman RP. Young children ( 12-yr) with type 1 diabetes mellitus have low rate of partial remission: diabetic ketoacidosis is an important risk factor. Pediatr Diabetes 2008: 9: 197– 201. 21Nimri R, Phillip M, Shalitin S. Children diagnosed with diabetes during infancy have unique clinical characteristics. Horm Res Paediatr 2007: 67: 263– 267. 22Dost A, Herbst A, Kintzel K et al. Shorter remission period in young versus older children with diabetes mellitus type 1. Exp Clin Endocrinol Diabetes 2007: 115: 33– 37. 23Chase HP, MacKenzie TA, Burdick J et al. Redefining the clinical remission period in children with type 1 diabetes. Pediatr Diabetes 2004: 5: 16– 19. Citing Literature Volume15, Issue7November 2014Pages 469-476 ReferencesRelatedInformation
Referência(s)